In our research, ML264, a KLF5 inhibitor, promoted the cognitive function of mice with AD and reduced the accumulation of Aβ in the brain of APP/PS1 mice by suppressing the BACE1 expression (Fig. 6). Here, APP is linked to Alzheimer disease.